NCT01759446View on ClinicalTrials.gov

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Opioid-Related Disorders
Interventions
DRUG

Placebo taken first

Snorted in both nostrils within 5 minutes; 48 hours washout between doses

DRUG

Generic H/A taken first

Snorted in both nostrils within 5 minutes; 48 hours washout between doses

DRUG

Vycavert taken first

Snorted in both nostrils within 5 minutes; 48 hours washout between doses

DRUG

Generic H/A plus i taken first

Snorted in both nostrils within 5 minutes; 48 hours washout between doses

DRUG

Generic H/A plus p taken first

Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Trial Locations (1)

84106

Lifetree Clinical Research, Salt Lake City

Sponsors
All Listed Sponsors
lead

Acura Pharmaceuticals Inc.

INDUSTRY

NCT01759446 - Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users | Biotech Hunter | Biotech Hunter